#1 Clinical Trials Search in Europe

Study on the Effects of Trastuzumab Deruxtecan in Patients with Advanced or Metastatic Cancer

1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment called Trastuzumab Deruxtecan, also known by its code name DS-8201a, on patients with advanced or metastatic cancer. Metastatic cancer is a type of cancer that has spread from its original site to other parts of the body. The study includes patients who are receiving this treatment as part of a clinical trial, expanded access, compassionate use, or standard treatment, regardless of the specific type of cancer they have.

The purpose of the study is to identify the best level of a specific molecule called ERBB2 mRNA that can predict how well patients will respond to Trastuzumab Deruxtecan in breast cancer. The study will involve collecting tumor samples from patients to analyze these levels and see how they relate to the overall response to the treatment. The study will also look at how these levels are associated with how long patients live without the cancer getting worse and their overall survival.

Throughout the study, researchers will also explore other factors, such as different types of breast cancer and immune-related genes, to see how they affect the response to Trastuzumab Deruxtecan. The study aims to develop a new way to predict who will benefit from this treatment and to understand any changes in the cancer that might lead to resistance to the treatment. The study is expected to continue until September 2027.

1 joining the study

Eligibility is determined for individuals diagnosed with advanced or metastatic cancer who are starting, receiving, or have received treatment with trastuzumab deruxtecan.

Written informed consent is required from the participant or their legally acceptable representative.

2 submission of tumor samples

A formalin-fixed, paraffin-embedded tumor tissue block from the most recently collected tumor tissue is submitted for central molecular analysis.

If a newer specimen is unavailable, a tissue block or a new biopsy may be required. Acceptable samples include core needle biopsies or excisional biopsies.

3 treatment administration

The treatment involves the administration of trastuzumab deruxtecan (Enhertu 100 mg) as a solution for infusion.

The medication is given through intravenous use, following the specific dosage and frequency as prescribed by the healthcare provider.

4 monitoring and assessments

Regular monitoring of health status and response to treatment is conducted.

Blood samples may be required for additional assessments.

5 end of study participation

The study aims to identify the optimal ERBB2 mRNA cut-point predictive of response to trastuzumab deruxtecan.

The study is estimated to conclude by September 30, 2027.

Who Can Join the Study?

  • Participants must be women or men who are 18 years old or older.
  • Participants should be starting, currently receiving, or have received treatment with Trastuzumab Deruxtecan for advanced or metastatic cancer. This is a specific type of cancer treatment.
  • The participant, or their legally acceptable representative, must provide written informed consent to join the study. This means they agree to participate after understanding the study details.
  • Participants need to provide a tumor tissue sample for analysis. This sample should be from the most recent tumor tissue collected and must be of good quality. If a newer sample is not available, an older one may be used, or the participant may agree to a new biopsy, which is a procedure to take a small piece of tissue for testing.
  • Acceptable tissue samples include core needle biopsies or other types of biopsies from different areas like skin or bone. However, samples from fine needle aspiration or certain fluid samples are not acceptable.
  • Participants who join the study before starting the experimental treatment must be able and willing to provide a blood sample.

Who Cannot Join the Study?

  • Patients who have not been diagnosed with advanced or metastatic cancer.
  • Patients who have not been treated with Trastuzumab Deruxtecan, which is a specific cancer treatment, in any form such as a clinical trial, expanded access, compassionate use, or standard treatment.
  • Patients who are male, as the study is only for female participants.
  • Patients who are part of a vulnerable population, which means groups that might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Jerez de la Frontera Jerez De La Frontera Spain

Other Sites

Site Name City Country Status
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Del Mar Barcelona Spain
Fundacion Instituto Valenciano De Oncologia Valencia Spain
Hospital Universitario Virgen Macarena Sevilla Spain
Virgen del Rocío University Hospital Sevilla Spain
Hospital Clinic De Barcelona Barcelona Spain
University Clinical Hospital Virgen De La Arrixaca Murcia Spain
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida Lleida Spain
Hospital Universitario De Canarias La Laguna Spain
Hospital Universitario Virgen De La Victoria Malaga Spain
Ivypshvl Cqpseh Dmfbkqxgvjrzibqfy L'hospitalet De Llobregat Spain
Frjmzbrsk Pqip Lz Icxmwhmtiiawx Bceotcpto Dnc Hrfgapgd Ubizsurjocjsy Lj Pyv Madrid Spain
Hmltvzse Vvqf dxxvnddq Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
01.11.2019

Trial locations

Investigated drugs:

Trastuzumab Deruxtecan (T-DXd; DS-8201a) is a medication used in this clinical trial. It is designed to treat certain types of breast cancer by targeting and attaching to a specific protein called HER2 found on the surface of some cancer cells. Once attached, it delivers a chemotherapy drug directly into the cancer cell, which helps to kill the cancer cells while minimizing damage to normal cells. This trial aims to find the best way to predict how well this medication will work for patients with breast cancer.

Investigated diseases:

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably, forming a tumor that can often be felt as a lump. It typically begins in the ducts or lobules of the breast and can spread to other parts of the body if not managed. The progression of breast cancer can vary, with some types growing slowly and others more rapidly. It is often categorized by hormone receptor status and HER2 protein levels, which can influence growth and treatment response. Early stages may not cause noticeable symptoms, but as it advances, symptoms like changes in breast shape, lumps, or skin changes may occur.

Trial ID:
2023-508830-33-00
Protocol code:
SOLTI-1804
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A Study of IPN01203 for Adults With Advanced or Metastatic Solid Tumors After Immune Checkpoint Inhibitor Treatment

    Recruiting

    1 1
    Investigated diseases:
    France Spain

  • Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France